貝瑞基因(000710.SZ):全資子公司檢測試劑盒通過註冊檢驗
格隆匯12月27日丨貝瑞基因(000710.SZ)公佈,公司全資子公司杭州貝瑞和康基因診斷技術有限公司於近日收到中國食品藥品檢定研究院下發的註冊檢驗報吿。名稱:地中海貧血基因檢測試劑盒(單分子測序法);檢驗結論:技術要求檢驗結果符合規定。
該試劑盒基於第三代高通量測序平台檢測地中海貧血相關基因突變,可應用於地中海貧血基因攜帶者篩查和輔助診斷。
本報吿期,由公司提供技術支持的三代地貧(即運用第三代測序技術進行地中海貧血基因檢測)多中心臨牀前瞻性研究成果在分子診斷期刊《The Journal of Molecular Diagnostics》上發表。該研究證明三代地貧覆蓋全面、精準度高、適用性廣,有助於提升全球地貧攜帶者篩查的效率和精度。
該次該試劑盒通過註冊檢測,將助力公司實現三代地貧基因檢測的商業轉化,加速推進三代測序的臨牀轉化應用。公司將繼續完成該試劑盒的醫療器械註冊申報流程,未來,該產品若獲批上市,將進一步完善公司三級預防產品管線,加強公司在基因測序領域的市場競爭力,預計將對公司未來經營產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.